

Curriculum Vitae

Christer Borgfeldt

Date of Birth: 16 May, 1962
Nationality: Swedish, EU citizen
Family: Married to Eva who is teacher at Kristianstad University, Kristianstad, Sweden.
Children Henrik (born 1991) and Anna (born 1993).

Licence as MD in Sweden, Norway and UK: Fully registered medical practitioner with specialist registration in Obstetrics and Gynaecology and Certified Sub-specialist in Gynaecological Oncology

Degrees

- Associate Professor in Obstetrics and Gynaecology at Lund University 2008
- Certified Sub-specialist in Gynaecological Oncology 2007
- Ph.D. Degree, Faculty of Medicine, University of Lund, Sweden 2001
- Specialist of Obstetrics & Gynaecology, 1995 (The Swedish National Board of Health and Welfare)
- Authorization to practice the Medical Profession as a Physician, Swedish licence 1990
- Medical Doctor Degree, Medical School 1982-1988, University of Lund, Sweden 1988

Professional experience

- Consultant at the Department of Obstetrics and Gynecology, University Hospital in Lund, Sweden since 1999
- Locum consultant at the Department of Obstetrics and Gynaecology, Nobles Hospital, Isle of Man in 2 weeks August 2006
- Locum consultant at Gynaecological Oncology Dept. University Hospital Tromsø, Norway in total 21 weeks (eleven times) 2004-2010
- Locum consultant at the Department of Obstetrics and Gynecology, Laerdal Hospital, Norway, two to three weeks a year 1997-2010
- Visiting Consultant at Northern Gynaecological Oncology Centre, Queen Elisabeth Hospital, Gateshead, United Kingdom, 3 months, March to May 2003
- Senior Registrar at the Dept. of Gynecological Oncology. The Norwegian Radium Hospital, Oslo Norway ½ year 1999
- Junior Consultant at the Department of Obstetrics and Gynecology, University Hospital in Lund, Sweden 1995-1999
- Registrar at the Department of Obstetrics and Gynecology including 1 year of abdominal surgery and ½ a year of anaesthesiology, Central Hospital in Kristianstad, Sweden 1990-1995
- Internship (AT) in Kristianstad, Sweden 2 years 1989-1990
- Clinical work at the Oto-Rhino-Pharyngeal clinic in Kristianstad, Sweden ½ year 1988
- Clinical work at the Infection clinic in Kristianstad, Sweden ½ year 1988

Inviten speaker

- Sentinel node procedure in vulvar and cervical cancer. Copenhagen, Denmark 2005
- HRT and coagulation. Copenhagen, Denmark 2005
- Speaker/faculty and guest surgeon at AGOICON 2005, Patna, Indien “Management of early epithelial ovarian cancer”
- Speaker and surgeon at video-transferred operation at Workshop “Advanced laparoscopy and robotic surgery for gynaecological malignancies” Lund 2006, Sweden
- Video demonstration at Conference in Lund, Sweden, 2007 "Evolution of Robotic Surgery in Europe",
- Speaker/faculty at the Swedish annual meeting in Obstetrics and Gynecology 2008 ”Gynecological Laparoscopic surgery”
- Speaker/faculty 2nd Sahlgrenska Meeting on Reproductive Medicine and Gynecology in Gothenburg 28 Mars 2009 ”Laparoscopic and robotic surgery in endometrialcancer“
- “The sentinel node concept in cervical cancer” Annual Swedish meeting in Radiology and Nuclear Medicine September 2009
- „Robot assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy in cervical and endometrial cancer“ The 18th Conference Gynecological Endoscopy, October 2009, Jesenik, Czeck Republic

Chairman for the Gynaecological Oncology working group in Sweden since December 2003.
Chairman for the Regional Cervical Dysplasia working group in the Southern County in Sweden since 2007

Principal Investigator

Pfizer study A0081153

GCP training in corporation with Phizer 2008

AMGEN study 20060289

Book chapters

“Ovarian tumors” in the book “Gynaecology” which was released in February 2010.

Original Articles:

1. The sentinel node concept in early cervical cancer performs well in tumors smaller than 2 cm. Darlin L, Persson J, Bossmar T, Lindahl B, Kannisto P, Måsbäck A, Borgfeldt C. *Gynecol Oncol*. 2010 May;117(2):266-9. Epub 2010 Feb 18.
2. Robot assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy with short and long term morbidity data. Persson J, Reynisson P, Borgfeldt C, Kannisto P, Lindahl B, Bossmar T. *Gynecol Oncol*. 2009 May;113(2):185-90. Epub 2009 Feb 28
3. Cleaved forms of the uPA receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Henic E, Borgfeldt C, Christensen IJ, Casslén B, Hoyer-Hansen G. *Clinical Cancer Research* 2008;14(18) 5785-5793.
4. Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. C Borgfeldt, C Iosif, A Måsbäck. Accepted in *European Journal of Obstetrics & Gynecology and Reproductive Biology* 2006.
5. Background factors influencing somatic and psychological symptoms in middle-age women with different hormonal status. A population-based study of Swedish women. C Li, C Borgfeldt, G Samsioe, J Lidfeldt, C Nerbrand. *Maturitas*. 2005 Nov-Dec;52(3-4):306-18. Epub 2005 Jun 20.
6. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Borgfeldt, C. Andolf, E. *Acta Obstet Gynecol Scand* 2004 (83(4)) pp 395-400
7. Low-dose oral combination of 17 beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1. Borgfeldt, C. Li, C. Samsioe, G. *Climacteric* 2004 (7) pp 78-85
8. High plasma concentrations of tissue plasminogen activator (tPA) is an independent marker for poor prognosis in patients with ovarian cancer. Borgfeldt C, Bendahl P-O, Fernö M, Casslén B. *Gynecol Oncol* 2003 (91(1)) pp 112-117
9. Menopause-related symptoms: What are the background factors? A prospective population-based cohort study of Swedish women (The Women's Health in Lund Area study). Li C, Samsioe G, Borgfeldt C, Lidfeldt J, Agardh CD, Nerbrand C. *Am J Obstet Gynecol* 2003 (189(6)) pp 1646-1653
10. High tumor tissue concentrations of urokinase plasminogen activator receptor is associated with good prognosis in ovarian cancer. Borgfeldt C, Fernö M, Bendahl P-O, Långström E, Gustavsson B, Willén R, Grenman S, Casslén B. *Int J Cancer* 2003 (107(4)) pp 658-665
11. Low-dose hormone therapy and carbohydrate metabolism. Li, C. Samsioe, G. Borgfeldt, C. Bendahl, P O. Wilawan, K. Aberg, A. *Fertil Steril*. 2003. (79(3)) pp 550-555
12. Changes in lipid and lipoprotein profile in postmenopausal women receiving low dose combinations of 17 β -estradiol and norethisterone acetate. Samioe, G. Li, Cairu. Borgfeldt, C. Wilawan, K. Åberg, A. Larsen, S. *Menopause* 2002 (9(5)) pp 335-342.
13. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Borgfeldt, C. Hansson, S R. Gustavsson, B. Masback, A. Casslén, B. *Int J Cancer* 2001 (92(4)) pp 497-502.
14. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyoma in a random sample of women age 25-40 years. Borgfeldt, C. Andolf, E. *Acta Obstet Gynecol Scand*. 2000 (79(3)) pp 202-207
15. Transvaginal sonographic ovarian findings in a random sample of women 25-40 years old. Borgfeldt C, Andolf E. *Ultrasound Obstet Gynecol* 1999 ;13(5):345-50.
16. High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma.

Borgfeldt, C. Casslén, B. Liu, C L. Hansson, S. Lecander, I. Astedt, B. Int J Cancer 1998 (79) pp 588-595.

17. The Hypereosinophilic Syndrome. C Borgfeldt, B Hansen, R Mantorpe. Scand J Rheum 17:51-54,1988